BIO-ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR SIMULTANEOUS DETERMINATION OF LEDIPASVIR AND SOFOSBUVIR DRUGS IN HUMAN PLASMA BY RP-HPLC METHOD
DOI:
https://doi.org/10.22159/ijcpr.2018v10i3.27223Keywords:
Ledipasvir, Sofosbuvir, Bio-analytical, RP-HPLC, PlasmaAbstract
Objective: A novel, sensitive and accurate high-performance liquid chromatography with ultraviolet/visible light detection (HPLC-UV/VIS) method for the quantification of ledipasvir and Sofosbuvir in plasma was developed and validated.
Methods: The analytes were extracted by liquid-liquid extraction method and chromatograph using a mobile phase consisting of acetonitrile and buffer solution, Methanol and Acetonitrile in the ratio of 200:600:200 (v/v) using Oyster BDS RP-C18 column. The flow rate 1.0 ml/min and UV detection at 238 nm were employed. The retention time for Ledipasvir and Sofosbuvir was 4.61 and 9.09 min respectively. Linearity for ledipasvir and Sofosbuvir was found to be in the range of 250-2000 ng/ml for both drugs respectively. Intra-and inter-day precision was less than 2% coefficient of variation.
Results: The method was validated as per the USFDA guidelines and the results were within the acceptance criteria for selectivity, sensitivity, linearity, precision, accuracy, recovery stability of the solution, the stability of solution in plasma and dilution integrity.
Conclusion: Majority of the HPLC method should be useful for monitoring human plasma drug concentrations, and pharmacokinetic studies in patients diagnosed with the Ledipasvir and Sofosbuvir formulations.
Downloads
References
Childs Kean LM, Hand EO. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection. Clin Ther 2015; 37:243-67.
Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 2012;19:560-7.
Yahia M. Global health: a uniquely Egyptian epidemic. Nature 2011;474:S12–S13.
Guofeng Cheng, Yang Tian, Brian Doehle, Betty Peng, Amoreena Corsa, Yu-Jen Lee, et al. In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob Agents Chemother 2016;60:1847-53.
Carrion AF, Gutierrez J, Martin P. New antiviral agents for the treatment of hepatitis C: ABT-450. Expert Opin Pharmacother 2014;15:711-6.
Jiang Y, Andrews SW, Condroski KR, Buckman B, Serebryany V, Wenglowsky S, et al. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease. J Med Chem 2014;57:1753-69.
Rose L, Bias TE, Mathias CB, Trooskin SB, Fong JJ. Sofosbuvir: a nucleotide NS5B inhibitor for the treatment of chronic hepatitis C infection. Ann Pharmacother 2014;48:1019–29.
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New England J Med 2014;370:1889–98.
Henderson JA, Bilimoria D, Bubenik M, Cadilhac C, Cottrell KM, Denis F, et al. Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores. Bioorg Med Chem Lett 25;2015:948-51.
Asselah T. Sofosbuvir for the treatment of hepatitis C virus. Expert Opin Pharmacother 2014;15:121-30.
Fung A, Jin Z, Dyatkina N, Wang G, Beigelman L, Deval J. Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother 2014;58:3636-45.
L Carey. What is the role of Sofosbuvir in treating hepatitis C infection. JAAPA 2015;28:16-9.
Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, et al. Sofosbuvir plus Ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet 2015;385:1098-106.
Sofia MJ, Bao D, Chang W, Du J, Nagarathnam D, Rachakonda S, et al. Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010;53:7202-18.
Kumari R, Nguyen MH. Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. Expert Opin Pharmacother 2015;16:739-48.
Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, et al. Treatment with ledipasvir and Sofosbuvir improves patient-reported outcomes: results from the ION-1,-2, and-3 clinical trials. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1,-2, and-3 clinical trials. Hepatology 2015; 61:1798-808.
Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015;313:1232-9.
Mohan Vikas P, Satyanarayana T, Vinod Kumar D, Mounika E, Sri Latha M, Anusha R, et al. Development and validation of new RP-HPLC method for the determination of Sofosbuvir in pure form. World J Pharm Pharm Sci 2006;5:775-81.
Food and Drug Administration. Guidance for industry; Bionalytical Method Validation, Center for Drug Evaluation and Research; 2001.
International Conference on Harmonization (ICH). Validation of Analytical Methods: Definitions and Terminology. ICH Q2 A; 1994.
International Conference on Harmonization (ICH). Validation of Analytical Methods: Methodology. ICH Q2 B; 1996.
Published
How to Cite
Issue
Section
